English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: to analyze the clinical effects and complications of rifapentine and rifampicin in patients with smear-positive pulmonary tuberculosis. Methods: from August 2013 to June 2017, 100 of the smear-positive pulmonary tuberculosis patients treated in our hospital were selected and divided into two groups according to treatment methods. Patients in the control group were treated with rifampicin + isoniazid + pyrazinamide + ethambutol, while patients in the observation group were treated with rifapentine + isoniazid + pyrazinamide + ethambutol. In addition to the nisus absorption rate, the cavity closure rate and the rate of sputum negative conversion after the treatment, the comparison was also applied on the level of peripheral blood T-lymphocyte subsets and the incidence of complications before and after the treatment. Results: compared with the control group, patients in the observation group had higher levels of CD8+, CD4+ and CD3+ in peripheral blood T lymphocyte subsets; the nisus absorption rate, cavity closure rate and the rate of sputum negative conversion in the observation group were higher after treatment, and the difference between the groups was statistically significant (P<0.05); the incidence of complications in the observation group was 6%, which was lower than that in the control group (22%). There was a statistically significant difference between the two groups (P<0.05). Conclusion: the clinical efficacy of rifapentine in smear-positive pulmonary tuberculosis patients is superior to that of rifampicin and therefore it worth being promoted.

Effects of Rifapentine and Rifampicin in Smear-positive Pulmonary Tuberculosis Patients and the Incidence Comparison of Complications